VERU

Veru Inc

Add to Watchlist

Advanced Chart

2.510

-0.22(-8.059%)1D

Line

Candle

YTD

High

2.860

Open

2.780

VWAP

2.62

Vol

244.24K

Mkt Cap

36.79M

Low

2.510

Amount

638.93K

EV/EBITDA(TTM)

Total Shares

146.38M

21.78M

EV/OCF(TTM)

P/S(TTM)

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-0.567

-5.55%

0.00

-100%

-0.600

-0%

-0.600

+20%

Estimates Revision

The market is revising No Change the revenue expectations for Veru Inc. (VERU) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -32.35%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-32.35%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast VERU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERU is 22.50 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.510

Low

20.00

Averages

22.50

High

25.00

Current: 2.510

Low

20.00

Averages

22.50

High

25.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-01-02

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-01-02

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2024-12-20

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2024-12-20

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Veru Inc (VERU.O) is -1.66, compared to its 5-year average forward P/E of -6.87. For a more detailed relative valuation and DCF analysis to assess Veru Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.87

Current PE

-1.66

Overvalued PE

17.47

Undervalued PE

-31.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.68

Current PS

2.73

Overvalued PS

21.49

Undervalued PS

-0.12